Objectives: To investigate clinical features associated with lack of response to MTX in juvenile idiopathic arthritis associated uveitis (JIA-U).
Methods: Clinical records of JIA-U patients were retrospectively reviewed. Differences among variables were assessed by Mann-Whitney and χ 2 or Fisher's exact tests as appropriate. Association between predictors and requirement of a biological disease modifying antirheumatic drug (bDMARD) was evaluated by univariate Cox regression analysis and Kaplan-Meier curves. A multivariable logistic model was applied to estimate strength of association, adjusting for potential confounders.
Results: Data from 99 JIA-U patients treated with MTX were analysed (82.8% female), with a mean follow up of 9.2 years and a mean age at uveitis onset of 5.7 years. In 65 patients (65.7%) at least one bDMARD to control uveitis was required. Children requiring a bDMARD for uveitis had lower age at JIA and uveitis onset, more frequent polyarticular course, higher frequency of bilateral uveitis at onset and higher prevalence of systemic steroids' use. Despite similar frequency of ocular damage at onset, MTX non responders showed a higher percentage of ocular damage at last visit. Younger age at JIA onset, polyarticular course and a history of systemic steroids' use resulted independent factors associated to lack of response to MTX at Cox regression analysis. Kaplan-Meier curves and the multivariate model confirms the independent role of both polyarticular course and systemic steroids' use.
Conclusions: Younger age at JIA onset, polyarticular course and a history of systemic steroids' use are predictors of a worse response to MTX in JIA-U.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/keae079 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum CS/DS, IGF-1, and IGFBP-3 as Biomarkers of Cartilage Remodeling in Juvenile Idiopathic Arthritis: Diagnostic and Therapeutic Implications.
Biomolecules
November 2024
Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, ul. Jedności 8, 41-200 Sosnowiec, Poland.
Cartilage destruction in juvenile idiopathic arthritis (JIA) is diagnosed, often too late, on basis of clinical evaluation and radiographic imaging. This case-control study investigated serum chondroitin/dermatan sulfate (CS/DS) as a potential biochemical marker of cartilage metabolism, aiming to improve early diagnosis and precision treatment for JIA. We also measured the levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) (using ELISA methods) in JIA patients ( = 55) both before and after treatment (prednisone, sulfasalazine, methotrexate, administered together), and analyzed their relationships with CS/DS levels.
View Article and Find Full Text PDFThe Role and Research Progress of ACPA in the Diagnosis and Pathological Mechanism of Rheumatoid Arthritis.
Hum Immunol
December 2024
Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei 230032, China; Laboratory Animal Center, Anhui Medical University, Hefei 230032, China. Electronic address:
An autoimmune condition known as rheumatoid arthritis (RA) is characterized by persistent polyarticular inflammation. Within two years of the disease's onset, irreparable bone and joint deterioration can occur as a result of the inflammatory course of the illness, leading to joint deformity and loss of function. In most patients diagnosed with RA, a range of autoantibodies, particularly anti-citrullinated protein antibodies (ACPA), can be detected months to years before the onset of clinically recognizable disease.
View Article and Find Full Text PDFDirect medical costs of polyarthritis in a pediatric hospital in Mexico.
Bol Med Hosp Infant Mex
November 2024
Unidad de Investigación en Epidemiología y Servicios de Salud, Área de Envejecimiento, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Article Synopsis
- Juvenile idiopathic arthritis (JIA) is a common childhood illness, with the polyarticular type affecting 63-66% of patients, and this study focused on its direct medical costs in a Mexican hospital.
- Analyzed records from January to September 2022 revealed that the average medical cost for a patient over the first 10 years of treatment was approximately $4,555, with medications constituting 82.7% of these costs, primarily from biological disease-modifying drugs (bDMARDs).
- The study concluded that the high cost of bDMARDs significantly impacts treatment expenses and suggested exploring generic options and negotiating prices to reduce overall costs for health institutions in Mexico.
Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial.
Arthritis Care Res (Hoboken)
November 2024
AbbVie Inc., North Chicago, Illinois.
Objective: This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).
Methods: In an open-label, phase 1 study (SELECT-YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight-based upadacitinib doses using a twice-daily oral solution or once-daily extended-release tablet based on their body weight and ability to swallow tablets. The study included a 7-day pharmacokinetic assessment, followed by a long-term efficacy and safety evaluation for up to 156 weeks, including an additional long-term safety cohort.
Clinical and laboratory features of juvenile idiopathic arthritis with wrist involvement: Results of a retrospective cohort study.
World J Clin Pediatr
September 2024
Hospital Pediatry, Saint Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia.
Article Synopsis
- Wrist inflammation in juvenile idiopathic arthritis (JIA) is linked to a more severe disease progression and increased treatment challenges, particularly in patients requiring biologic therapies.
- The study analyzed data from 753 JIA patients, revealing that wrist involvement is common in various JIA types and is associated with more systemic inflammation markers and complications, especially in females.
- Patients with wrist arthritis had a lower likelihood of achieving remission and a higher chance of needing biologics, highlighting the importance of early and intensive treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!